Endocrinology | Pipeline Prospector | PharmaCompass.com

[{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Denosumab","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"BeiGene","amount2":2.7999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"BeiGene \/ Amgen","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Amgen"},{"orgOrder":0,"company":"Betagenon","sponsor":"Ivy Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"O304","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Betagenon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Betagenon \/ Ivy Capital","highestDevelopmentStatusID":"8","companyTruncated":"Betagenon \/ Ivy Capital"},{"orgOrder":0,"company":"Ro","sponsor":"Greenstone LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ro","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ro \/ Greenstone","highestDevelopmentStatusID":"12","companyTruncated":"Ro \/ Greenstone"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"PKX-001","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"SSTR","graph1":"Endocrinology","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Nestle Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Science"},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Gut microbiome based therapeutics","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"","sponsorNew":"MRM Health \/ DuPont","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health \/ DuPont"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Exenatide","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ National Securities Corporation"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pirfenidone","moa":"IL-6\/TNF-alpha","graph1":"Endocrinology","graph2":"Phase I","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"PureTech Health \/ Not Applicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Betahistine Dihydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"JDRF T1D","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ JDRF T1D","highestDevelopmentStatusID":"4","companyTruncated":"Repertoire Immune Medicines \/ JDRF T1D"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"IDG-16177","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Ildong","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Ildong"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Crinecerfont","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neurocrine Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ SVB Leerink"},{"orgOrder":0,"company":"Napo EU","sponsor":"Atlas Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"NP-500","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Napo EU","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Napo EU \/ Atlas Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Napo EU \/ Atlas Sciences"},{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Delpharm Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Delpharm Group \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Delpharm Group \/ AzurRx BioPharma"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Poxel \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"rhGAD65","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Creapharm","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"MS1819","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Creapharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Creapharm \/ AzurRx","highestDevelopmentStatusID":"8","companyTruncated":"Creapharm \/ AzurRx"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Levoketoconazole","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PRV-101","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Recombinant pluripotent stem cell-derived pancreatic islet beta cells","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ Sernova"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"saRNA","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Gene Therapy-AAV8","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Regenxbio \/ Ultragenyx","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio \/ Ultragenyx"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Therapeutics \/ QVT"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"AZP-3601","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alize\u0301 Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Alogliptin Benzoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Celltrion","highestDevelopmentStatusID":"12","companyTruncated":"Takeda Pharmaceutical \/ Celltrion"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Somatrogon","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"OPKO Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OPKO Health \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin Glargine","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lannett Company, Inc. \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Lannett Company, Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dasiglucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ladarixin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dompe Farmaceutici \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Diasome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diasome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diasome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Diasome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Mankind Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Provention Bio","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ SVB Leerink"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati Rare Diseases \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati Rare Diseases \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ertugliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Pramlintide","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Apabetalone","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GL0034","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"BI 456906","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoMolecular Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"IMT-002","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ImmunoMolecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ImmunoMolecular Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ImmunoMolecular Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ Jefferies"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levoketoconazole","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"PTH(1-34)","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"ProLynx \/ National Institute of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institute of Health"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CS02","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center Laboratories \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ Not Applicable"},{"orgOrder":0,"company":"University of Pittsburgh","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"GPX-002","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"University of Pittsburgh","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"University of Pittsburgh \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"University of Pittsburgh \/ National Institutes of Health"},{"orgOrder":0,"company":"MBX Biosciences","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"MBX Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"MBX Biosciences \/ Frazier Healthcare Partners","highestDevelopmentStatusID":"4","companyTruncated":"MBX Biosciences \/ Frazier Healthcare Partners"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Cediprof"},{"orgOrder":0,"company":"PreveCeutical Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"siRNA","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PreveCeutical Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PreveCeutical Medical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PreveCeutical Medical \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Not Applicable"},{"orgOrder":0,"company":"Enthera Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Ent001","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Enthera Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Enthera Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"4","companyTruncated":"Enthera Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Poxel","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Sumitomo Dainippon Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ Sumitomo Dainippon Pharma"},{"orgOrder":0,"company":"Recordati","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Osilodrostat Phosphate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recordati \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Recordati \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Relacorilant","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"W. L. Gore & Associates","sponsor":"ViaCyte Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Stem cell-derived pancreatic islet cell progenitors","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"W. L. Gore & Associates","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"W. L. Gore & Associates \/ ViaCyte","highestDevelopmentStatusID":"4","companyTruncated":"W. L. Gore & Associates \/ ViaCyte"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Dorzagliatin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0.64000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.64000000000000001,"dosageForm":"Tablet","sponsorNew":"Hua Medicine \/ Bayer","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Bayer"},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AG019","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precigen \/ Not Applicable"},{"orgOrder":0,"company":"Balticgruppen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Balticgruppen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Balticgruppen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Balticgruppen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"ProtoKinetix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Antiaging Glycopeptide","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"ProtoKinetix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProtoKinetix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ProtoKinetix \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Chiasma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Octreotide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Chiasma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chiasma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chiasma \/ Not Applicable"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dulaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paltusotine","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Crinetics Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"GAD-alum","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Diamyd Medical AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Not Applicable"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Levoketoconazole","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Strongbridge Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Strongbridge Biopharma \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Strongbridge Biopharma \/ Jefferies"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Totum-63","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Insulin icodec","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Poxel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Poxel \/ Not Applicable"},{"orgOrder":0,"company":"vTv Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"TTP399","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"vTv Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"vTv Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"vTv Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Series C Financing","leadProduct":"CT-868","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ Amgen","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ Amgen"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Eftansomatropin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"I-Mab Biopharma \/ Genexine","highestDevelopmentStatusID":"8","companyTruncated":"I-Mab Biopharma \/ Genexine"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cinacalcet Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enavogliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daewoong Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Testosterone Undecanoate","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lipocine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipocine \/ Not Applicable"},{"orgOrder":0,"company":"Dexcom","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Insulin Lispro","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Dexcom","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dexcom \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Dexcom \/ Eli Lilly"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antibodies","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Novo Nordisk"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ EffRx","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Group \/ EffRx"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"TransCon PTH","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendis Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ascendis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"IM Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methyldopa","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"IM Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IM Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"IM Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Axiom Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Endocrinology","graph2":"IND Enabling","graph3":"Cure Pharmaceutical","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Film","sponsorNew":"Cure Pharmaceutical \/ Axiom Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"Cure Pharmaceutical \/ Axiom Capital Management"},{"orgOrder":0,"company":"Provention Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Teplizumab","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Provention Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Provention Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Provention Bio \/ Not Applicable"},{"orgOrder":0,"company":"CymaBay Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"MBX-2982","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"CymaBay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CymaBay Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CymaBay Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lumos Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibutamoren","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Lumos Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lumos Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lumos Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"ZT-01","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zucara Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Zucara Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"ChromaDex, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sotagliflozin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Lexicon pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Asymchem Laboratories","sponsor":"AzurRx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MS1819","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Asymchem Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Asymchem Laboratories \/ AzurRx BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Asymchem Laboratories \/ AzurRx BioPharma"},{"orgOrder":0,"company":"Oramed Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Oramed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oramed Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oramed Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tolmar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Leuprolide Acetate","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tolmar \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ Not Applicable"},{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Testosterone","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Aleor Dermaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Dermaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SteroTherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluasterone","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"SteroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"SteroTherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"SteroTherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Metavant Sciences","sponsor":"Sumitomo Pharma Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imeglimin Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Metavant Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metavant Sciences \/ Sumitomo Dainippon","highestDevelopmentStatusID":"10","companyTruncated":"Metavant Sciences \/ Sumitomo Dainippon"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Emisphere Technologies","amount2":1.8,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Tirzepatide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Arecor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Ultra-concentrated Rapid Acting Insulin Aspart","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Not Applicable"},{"orgOrder":0,"company":"Emisphere Technologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Emisphere Technologies","amount2":1.8,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":1.8,"dosageForm":"Tablet","sponsorNew":"Emisphere Technologies \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Emisphere Technologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Christian Social Services Commission","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SOUTH AFRICA","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Rh-insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Christian Social Services Commission","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Christian Social Services Commission \/ Biocon Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Christian Social Services Commission \/ Biocon Biologics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Megapharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Glucagon","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Megapharm","highestDevelopmentStatusID":"12","companyTruncated":"Xeris Pharmaceuticals \/ Megapharm"},{"orgOrder":0,"company":"University of Geneva","sponsor":"Tonix Pharmaceuticals Holding